Acurx Pharmaceuticals Secures $1.1M for Clinical Trials

Introduction

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is a publicly held, clinical-stage biopharmaceutical company headquartered in Staten Island, New York. The company is developing a new class of small-molecule antibiotics that selectively target Gram-positive pathogens by inhibiting the bacterial enzyme DNA polymerase IIIC. Its lead candidate, ibezapolstat, is Phase 3-ready for the treatment of Clostridioides difficile infection (CDI).

Corporate Structure

Acurx employs between 11 and 50 people, including a senior management team with significant industry experience:

• David P. Luci, Co-Founder, President & Chief Executive Officer, formerly President & CEO of Dipexium Pharmaceuticals and a corporate lawyer and CPA.
• Robert J. DeLuccia, Co-Founder & Executive Chairman, who has previously held leadership roles in multiple antibiotic drug-development companies.
• Robert G. Shawah, CPA, Co-Founder & Chief Financial Officer, previously served as Chief Accounting Officer of Dipexium Pharmaceuticals and has experience in commercial real estate finance.

The company maintains an Investor Relations office at 259 Liberty Avenue, Staten Island, NY 10305.

Recent Developments and News

• March 10, 2025: Acurx closed a registered direct offering for gross proceeds of $1.1 million, issuing 2,745,000 shares at $0.40 and concurrent unregistered warrants to purchase 8,235,000 shares at a $0.40 exercise price.
• May 29, 2025: The SEC declared effective Acurx’s Form S-1 registration and filed a Prospectus (Rule 424(b)(3)) for up to 10,899,258 shares, trading under the ticker ACXP at a last price of $0.388 on May 28.
• Q1 2025 Lobbying Disclosure: Acurx reported $20,000 in lobbying expenditures related to Department of Defense appropriations (biodefense preparedness) and Health and Human Services appropriations (antibiotic research and clinical trials).
• Insider Trading (past six months): Six insider purchases totaling approximately $160,000. Key participants include CEO David P. Luci and Executive Chairman Robert J. DeLuccia.
• Institutional Activity (Q4 2024–Q1 2025): Thirteen institutional investors increased positions, with Vanguard adding 67,500 shares in Q1 2025, while eight reduced holdings.
• May 2025 Conference Presentation: Results from a collaboration with Leiden University Medical Center were presented at the FASEB Conference, focusing on ibezapolstat’s mechanism of action and Phase 2 trial results, which reported a 96% clinical cure rate.

Financial and Strategic Analysis

As of June 17, 2025, ACXP shares traded at $1.06, reflecting a 245.16% increase with a daily volume of 89.7 million shares. The March direct offering and the May prospectus filing indicate ongoing capital-raising efforts to fund Phase 3 trials and general corporate purposes. Acurx is categorized as an “emerging growth company,” which may indicate reduced reporting requirements. Its reliance on equity financing and the speculative nature of clinical-stage biotechnology present both investment opportunities and risks.

Key financial events include:

• Direct offering raised $1.1 million before fees.
• Potential resale of nearly 11 million shares under the Lincoln Park agreement.
• Institutional demand evidenced by significant additions from Vanguard, Morgan Stanley, and Susquehanna.

Market Position and Industry Context

Antibiotic resistance remains a critical public health issue, with CDI, MRSA, VRE, and drug-resistant Streptococcus pneumoniae identified as priority pathogens by the WHO, CDC, and FDA. Acurx's GPSS® (Gram-positive selective spectrum) aims to address these concerns while maintaining gut microbiome diversity. Its pipeline extends beyond ibezapolstat to include early-stage programs for acute bacterial skin and skin structure infections (ABSSSI) and inhaled anthrax.

Competitive factors include:

• Changes in C. difficile susceptibility patterns against existing treatments like fidaxomicin.
• High regulatory and development costs for new antibiotics.
• Partnerships and collaborations that may enhance the understanding of pol IIIC inhibition mechanisms.

tl;dr

Acurx Pharmaceuticals closed a $1.1 million direct offering on March 10, 2025, and received SEC effectiveness for its Form S-1 on May 29, 2025, enabling a potential resale of up to 10.9 million shares. Its lead candidate, ibezapolstat, is Phase 3-ready for CDI, supported by May 2025 FASEB data. Institutional investors and insiders have increased their stakes in Q4 2024–Q1 2025, as the company prepares for international Phase 3 trials and positions itself within the antibiotic-resistance market.